Medicare Limits Payments for Biogen’s Alzheimer’s Drug

Posted on AllSides April 7th, 2022
From The Center

Medicare will deny routine payment for Biogen Inc.’s Alzheimer’s disease drug Aduhelm, finalizing an unusually strict policy that will require patients to enroll in clinical trials so the government will pay for the drug.

The Medicare policy, which government officials announced on Thursday, is expected to significantly constrict the number of patients taking Aduhelm, as well as its commercial potential.

The policy will also apply to drugs that are cleared in the future for Alzheimer’s with a conditional approval, as Aduhelm was, and that require a lower bar of evidence than traditional approvals.

“We...

Read full story
Some content from this outlet may be limited or behind a paywall.

Wall Street Journal (News)

AllSides Media Bias Rating: Center
AllSides Media Bias Rating: Center
106307/83984
See full bias rating for Wall Street Journal (News)
Learn about media bias
https://www.wsj.com/articles/medicare-limits-payments-for-biogens-alzheimers-drug-11649365397

More News about Healthcare from the Left, Center and Right

From the Left

From the Center

From the Right